Logo

Biocon Biologics and Viatris Receive CHMP's Positive Opinion for Abevmy (biosimilar- bevacizumab)

Share this

Biocon Biologics and Viatris Receive CHMP's Positive Opinion for Abevmy (biosimilar- bevacizumab)

Shots:

  • The CHMP has adopted a positive opinion recommending the marketing authorization of Abevmy (inj. bevacizumab 100 & 400mg)- which is co-developed by Biocon and Viatris
  • The companies expect the EC’s decision in May’2021- which will grant the approval in 27 EU member countries and EEA member states of Norway- Iceland and Liechtenstein. For the UK- MHRA’s reliance procedure” will be followed- and the UK marketing authorization can be expected shortly after the EC decision
  • Abevmy is a biosimilar referencing Roche’s Avastin and is a humanized mAb that selectively binds to human VEGF and neutralizes its biological activity. Abevmy is available for all indications of its reference products

 ­ Ref: Biocon Biologics  | Image: PRNewswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions